- Research article
- Open Access
Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease
© Gu et al; licensee BioMed Central Ltd. 2007
Received: 04 April 2007
Accepted: 30 April 2007
Published: 30 April 2007
A critical issue in understanding Huntington's disease (HD) pathogenesis is how the ubiquitously expressed mutant huntingtin (mhtt) with an expanded polyglutamine repeat can cause selective toxicity of striatal and cortical neurons. Two potential cellular models may contribute to such specificity: expression of mhtt in these vulnerable neurons alone may be sufficient to result in their dysfunction and/or degeneration (cell-autonomous model); or mhtt in other cell types can elicit pathological cell-cell interactions to cause the vulnerable neurons to become dysfunctional and be at risk for degeneration (cell-cell interaction model). To distinguish between these two models, we have selectively expressed a neuropathogenic fragment of mhtt-exon1 in striatal medium spiny neurons (MSNs) by crossing a conditional mouse model of HD with a striatal-specific Cre mouse line. In this striatal model of HD, we observed progressive and cell-autonomous nuclear accumulation of mhtt aggregates in MSNs. Surprisingly, unlike the mouse model expressing mhtt-exon1 in all the neurons in the brain, the striatal model lacks significant locomotor deficits and striatal neuropathology including gliosis and dark degenerating neurons. Electrophysiological findings from acutely dissociated MSNs revealed a cell-autonomous deficit in N-methyl-d-aspartate (NMDA) receptor sensitivity to Mg2+, a deficit also present in other mouse models of HD. In conclusion, this study provides the first in vivo genetic evidence that pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of HD, and suggests a ''two-hit'' hypothesis in which both cell-autonomous toxicity and pathological cell-cell interactions are critical to HD pathogenesis.
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder characterized clinically by movement abnormalities (i.e. chorea), psychiatric symptoms, and cognitive deficits . HD belongs to a group of neurodegenerative disorders caused by polyglutamine repeat (polyQ) expansion. In HD, the CAG repeat mutation encoding the polyQ repeat lies in exon 1 of the mutant huntingtin gene: the normal repeat is less than 36 while the mutant repeat ranges from 36 to about 120 [2, 3]. In all polyglutamine disorders including HD, the polyQ repeat length is inversely correlated with the age of onset of symptoms [4–8].
A critical question in understanding pathogenesis of HD as well as other polyQ disorders is how the widely expressed mutant polyQ protein can cause highly selective neuronal toxicity. In each polyQ disorder, distinct subsets of neurons in the CNS are selectively affected. The most affected neuronal type in HD is the striatal medium spiny neuron (MSN), with the vast majority of MSNs degenerating in the advanced stage of the disease. The second most affected neuronal population in HD is the cortical pyramidal neuron (CPN), particularly those that lie in the deep cortical layers [9, 10]. Contrary to the significant neurodegeneration in the striatum and cortex, neurons in the cerebellum and other sub-cortical brain regions are usually spared in the majority of HD patients. The latter brain regions may exhibit some neurodegeneration only in the most severely affected, juvenile-onset HD patients who have relatively longer polyQ repeats . Since mutant huntingtin (mhtt) is ubiquitously expressed in the brain and peripheral tissues [11–13], the selective pattern of neuronal toxicity in HD cannot be explained by the expression pattern of mhtt [14–17].
Conceptually, there are at least two cellular models that could account for the selective neuronal toxicity in HD. In the first, cellular toxicity of mhtt within the vulnerable neurons alone is sufficient to elicit progressive dysfunction and degeneration of these neurons (cell-autonomous model). In the second, pathological cell-cell interactions elicited by mhtt expression in other cell types are necessary or even sufficient to cause the dysfunction and degeneration of the vulnerable neurons (cell-cell interaction model). Full length mhtt as well as its toxic N-terminal fragments, which are known to be generated by proteolysis [9, 18–21], can elicit a variety of cell-autonomous toxicities including synaptic dysfunction, defective endocytosis, axonal transport deficits, mitochondria abnormalities, and transcriptional dysregulation . Recent studies also suggest that mhtt can generate pathological cell-cell interactions including aberrant corticostriatal neurotransmission , abnormal glial function , and reduction of cortical brain derived neurotrophic factor (BDNF)  which is neurotrophic to MSNs . Despite the rich literature demonstrating the presence of both cell-autonomous toxicity and pathological cell-cell interactions in HD models, their relative contributions to disease pathogenesis remain poorly defined.
In the current study, we used the RosaHD model to address whether pathological cell-cell interactions are required for striatal pathogenesis in vivo. By crossing RosaHD mice with Dlx5/6-Cre mice, we have selectively switched on mhtt-exon1 expression in all striatal MSNs and a subset of cortical interneurons. We found that progressive nuclear accumulation of mhtt aggregates in the striatum is a cell-autonomous process, but the striatal model lacks the locomotor deficit and significant striatal neuropathology which are evident in the pan-neuronal model of HD. However, electrophysiological analyses revealed that both the striatal model and pan-neuronal model exhibit cell-autonomous dysfunctions in NMDA receptor-mediated responses. The present analyses demonstrate that pathological cell-cell interactions are required for striatal pathogenesis in the RosaHD mouse model. Furthermore, our regionally-specific HD mice support a "two-hit" hypothesis in which both cell-autonomous toxicity and abnormal cell-cell interactions contribute to HD pathogenesis in vivo.
Generation of the striatal model of HD
To selectively express mhtt-exon1 in striatal MSNs, we crossed RosaHD mice with the well-characterized Dlx5/6-Cre mice, which have been shown to mediate LoxP recombination in striatal MSNs, and in a subset of cortical and olfactory interneurons during embryonic development between E11 and P0 [28, 29]. To demonstrate the regional specificity of mhtt-exon1 expression in the RosaHD/Dlx5/6-Cre (termed the striatal model), we performed immunostaining in 6 month old double transgenic mice with the EM48 antibody, a rabbit polyclonal antibody raised against the N-terminal of human htt which is highly specific to the aggregated forms of mhtt in HD patients and HD mouse brains . Consistent with our prior observation that mhtt aggregation in the RosaHD cortical and pan-neuronal models is a cell-autonomous process, we detected selective accumulation of EM48 mhtt, in the form of diffuse nuclear staining but not large nuclear inclusions, in the striatum of the striatal model (Fig. 1B). There were a few cells with EM48 diffuse nuclear staining in the cortex (Fig. 1C), but little EM48 nuclear staining was detected in other brain regions including the cerebellum (Fig. 1D) and brain stem (Fig. 1E), etc. EM48 (+) staining was not observed in wildtype (WT) littermate controls or in the striatal model in at 1 month of age (data not shown), demonstrating that the diffuse nuclear accumulation of EM48 (+) mhtt in the striatum is a cell-autonomous and progressive process in the striatal model of HD.
Lack of significant motor deficits and striatal pathology in the striatal model of HD
Cell-autonomous NMDA receptor dysfunction in the striatal model of HD
To further characterize similarities and differences among models we assessed NMDA receptor function in acutely dissociated striatal MSNs in all three models in mice at 6 months of age. First we examined membrane properties of the dissociated neurons. The only significant change in membrane properties occurred in the pan-neuronal model in which membrane capacitance was smaller in the transgenic cells (12.1 ± 0.6 pF in WTs versus 10.8 ± 0.6 pF in transgenics; p < 0.05, t-test), suggesting a smaller neuron size. There was no significant change in capacitance in the cortical and striatal models. Input resistance was similar in WT and transgenic cells in all three groups.
To address the role of pathological cell-cell interactions in striatal pathogenesis in HD mousemodels in vivo, we developed a striatum-specific mouse model of HD which expresses a neuropathological fragment of mhtt (mhtt-exon1) selectively in striatal MSNs and in a subset of cortical interneurons but not in the CPNs or other neurons in the brain. This model reveals that striatal-specific expression of mhtt is sufficient to elicit cell-autonomous mhtt nuclear accumulation and aggregation and NMDA receptor dysfunction. However, cell-autonomous toxicity of mhtt is insufficient to elicit progressive locomotor deficits and significant striatal pathology including gliosis and dark neuron degeneration, all of which are observed in the pan-neuronal models of HD .
Responses to NMDA and their blockade by Mg2+ were altered in mutant compared to WT mice in the pan-neuronal and striatal model, but not in the cortical model. This indicates that the presence of mhtt in CPNs alone does not lead to changes in NMDA receptor-mediated currents in the striatum. The changes in NMDA receptor function in the pan-neuronal and striatal models were different, with smaller NMDA currents in mutant cells from the pan-neuronal model, and larger NMDA currents in mutant cells from the striatal model. However, in both models Mg2+ blockade of NMDA currents was reduced, similar to effects in R6/2 mice of 15–40 days . Previous studies on dissociated neurons in R6/2 mice have shown both increases and decreases of glutamate receptor-mediated currents depending on the age and the progression of the phenotype. In young R6/2 mice (15–40 days), NMDA and AMPA currents were increased, while in older mice (80 days), they were decreased [31, 32]. Similarly, biphasic changes for NMDA and AMPA currents were observed in CPNs in young and older R6/2 mice .
At the present time it is difficult to determine the mechanisms underlying this complex set of electrophysiological changes in different models at the same age. The presence of mhtt in striatal neurons appears to be necessary to alter Mg2+ sensitivity. This effect might be related to alterations in NMDA receptor subunits [34–36]. The decrease in magnitude of the NMDA current in the pan-neuronal model might be related to changes in cortical inputs which have been shown to occur in this and other transgenic mouse models of HD [27, 37]. In contrast, the increase in current magnitude in the striatal model might reflect the possibility that alterations in the cortex no longer contribute to striatal anomalies.
Our analyses of the regional models of HD are consistent with prior evidence supporting the possible role of cell-cell interactions in HD striatal pathogenesis. First, excitotoxicity is thought to contribute to striatal pathogenesis in HD. The mechanisms underlying such toxicity are not completely clear, but may include both cell-autonomous mechanisms such as alteration in NMDA receptor function in the MSNs [17, 33, 38–40] or non-cell-autonomous mechanisms, such as enhanced glutamate release from CPNs [40–43] or reduced glutamate clearance [44–46]. Our in vitro electrophysiological analysis clearly confirms prior results with R6/2 mice , and suggests that altered Mg2+ blockade of NMDA receptors in striatal MSNs may contribute to striatal excitotoxicity. Another mechanism supporting cell-cell interactions in HD is the role of cortical BDNF in striatal pathogenesis suggesting that the transcription and axonal transport of BDNF is diminished in HD models [25, 47]. Since cortex-specific deletion of BDNF is known to elicit progressive striatal degeneration in mice , BNDF reduction will contribute to striatal pathogenesis in HD. Finally, non-neuronal cells, particularly astrocytes, are also affected in HD and HD mice. Studies using primary cell culture demonstrate that astrocytes derived from R6/2 mice have reduced capacity to transport glutamate, and thus cannot protect mutant neurons from glutamate toxicity as well as astrocytes of WTs . Studies using mouse models of other neurodegenerative disorders, such as amyotrophic lateral sclerosis , frontotemporal dementia , synucleinopathy , and spinocerebellar ataxia 7 (another polyQ disorder) , provide in vivo genetic evidence that non-neuronal cells may contribute to neurodegeneration. Thus, converging evidence suggests pathological cell-cell interaction as a common cellular mechanism in multiple neurodegenerative disorders.
Our analyses of the striatal model of HD also indicate that caution should be used when interpreting neurodegenerative phenotypes in HD cellular models over-expressing pathogenic fragments of mhtt. These cellular models have been particularly valuable for rapid dissection of molecular mechanisms underlying the mhtt toxicity. Since neurodegeneration in such models occurs rapidly in days and is due to cell-autonomous toxicity of mhtt, and our striatal model of HD demonstrates that cell-autonomous toxicity of mhtt-exon1 in vivo is insufficient to elicit significant neuropathology, the rapid neurodegenerative process observed in cellular models may reflect different mechanisms than the slow degenerative process which occurs in the in vivo models. The latter may require pathological cell-cell interactions. We suggest that the cellular models are valuable for rapid identification of candidate molecular mechanisms underlying both cell-autonomous and non-cell-autonomous toxicity of mhtt, and these mechanisms should be validated in in vivo genetic models of HD.
We have developed a novel genetic mouse model in which a neuropathogenic fragment of mhtt-exon1 is selectively expressed in striatal MSNs and a subset of cortical interneurons. We demonstrate that the striatal model of HD exhibits cell-autonomous accumulation of nuclear mhtt aggregates, and alterations in NMDA receptor function, but this model lacks robust striatal neuropathology (i.e. gliosis and dark neuron neurodegeneration) and progressive motor deficits. Taken together these findings emphasize that pathological cell-cell interactions are necessary for striatal pathogenesis in vivo in genetic mouse models of HD.
The RosaHD mouse is a conditional HD mouse model in which expression of mhtt-exon1 with 103 glutamine repeats is completely dependent on Cre-mediated excision of a transcription termination sequence flanked by two Cre binding sites (LoxP) (Fig 1A). RosaHD mice were bred with Dlx5/6-Cre mice  to generate the striatal model that expresses mhtt in striatal MSNs and cortical interneurons. The pan-neuronal and cortical models were generated by crossing RosaHD mice with Nestin-Cre and Emx-Cre mice as reported previously . RosaHD mice were maintained as 129Sv and C57BL/6 hybrids. Dlx5/6-Cre mice were maintained on C56BL/6 background. The male and female F1 mice from crosses between RosaHD and Cre mice were used in the present experiments. Mice were group housed in a clean facility with free access to food and water. Animal breeding and experiment protocols were in accordance with the National Institute of Health Guidelines for use of live animals and approved by the Animal Research Committee at UCLA.
Automatic Open Field Test
Twenty naïve transgenic and 22 WT littermates at 6 months of age and 15 transgenic and 14 WT littermates at 12 month were tested with an Automatic Open Field system (Tru Scan 99; Coulbourn Instruments, Allentown, PA). A mouse was placed in an open field arena for 15 min during the dark phase of the 6:00 PM–6:00 AM dark-light cycle. Locomotor activity and the proportion of time spent in the center and margin areas were recorded and calculated using the Tru Scan 99 Software.
Transgenic and their WT littermates were transcardially perfused with ice-cold 0.1 M phosphate buffer (PB, pH 7.2), followed by ice cold 4% paraformaldehyde with 0.2% glutaraldehyde in 0.1 M PB (pH 7.4). After 6 h postfix in 4% paraformaldehyde buffer as above, brains were equilibrated with 30% sucrose by shaking at 4°C until the brains sank to the bottom of the container. Thirty-five μm coronal or saggital brain sections were cut using a Leica CM 1850 cryostat and stored at -20°C. Free-floating sections were processed for immunohistochemistry staining as described previously . The following primary antibodies were used: rabbit anti-human htt EM48 antibody (1:300), mouse anti-GFAP antibody (1:10000, Sigma), goat anti-mouse Darpp32 antibody (1:1000, Chemicon), mouse anti-GABA (1: 1000, Sigma). EM48 and GFAP immunostaining were visualized by using diaminobenzidine as the chromogen (Pierce); Goat anti-rabbit Alexa Fluor 488 (Molecular Probes) and goat anti-rabbit Texas-red (DAKO), goat anti-mouse Alexa Flour 546 (Molecular Probes) were used for EM48/Darpp32 and EM48/GABA double immunofluorescent stainings, respectively. The EM48/Darpp32 double immunofluorescence staining was carried out by using the two step sequential method after verification of antibody specificity in control sections. Briefly, brain sections were blocked with normal goat serum and stained with EM48 antibody and Alexa Fluor 488 secondary antibody. The sections were further washed and blocked with normal goat serum, then stained with Darpp32 antibody and Texas-red secondary antibody. All steps in the second round of Darpp32 immunostaining were carried out in the dark. Quantitative analyses of reactive gliosis were performed blind with respect to genotype as described .
Two 12 month-old pan-neuronal, cortical and striatal model mice and their WT littermates were trancardially perfused with ice-cold 0.1 M PB (pH 7.2), followed by ice cold 2% paraformaldehyde with 2% glutaraldehyde in 0.1 M PB (pH 7.4). The brains were dissected out and immersed in 0.1 M PB for 6 h. 100 μm sections were sliced using a vibratome and treated with 1% osmic acid for 2 h. After washing with 0.1 M PB, brain sections were dehydrated in ascending concentrations of ethanol and propylene oxide/Eponate 12(1:1) and embedded in Eponate 12(Ted Pella Inc., Redding, CA). Ultrathin sections (60 nm) were cut using a Leica UltracutS ultramicrotome. Thin sections were counterstained with 5% aqueous uranyl acetate for 5 min followed by Reynolds lead citrate for 5 min and examined using a Hitachi (Tokyo, Japan) H-7500 electron microscope.
Mice 8–10 months of age were used. The following are the numbers of mice and cells recorded from each group: 4 pan-neuronal model mice (14 cells) and 3 WT littermate controls (10 cells), 4 striatal model mice (21 cells) and 4 WT littermate controls (19 cells), 4 cortical model mice (25 cells) and 4 WT littermate controls (14 cells). Details of procedures for acute dissociation and recording have been published . Briefly, mice were anesthetized with halothane, transcardially perfused and decapitated. Brains were dissected and sliced coronally and the dorsal part of the striatum was dissected for acute dissociation of neurons. Cells were recorded in an external Mg2+ free external solution (in mM): 135 NaCl, 20 CsCl, 5 BaCl2, 10 glucose, 10 HEPES, 0.02 glycine and 0.0003 tetrodotoxin (TTX, pH 7.4, 300–310 mOsm). The external recording solution contained Ba2+, instead of Ca2+, to minimize the influence of Ca2+-mediated transduction systems. The presence of Cs+ and TTX in the external solution blocked some voltage-gated K+ and Na+channels, respectively. The internal pipette solution contained (in mM): 175 N-methyl-D-glucamine (NMDG), 40 HEPES, 2 MgCl2, 10 ethylene glycol-bis (β-aminoethyl ether)-N, N, N', N'-tetraacetic acid (EGTA), 12 phosphocreatine, 2 Na2ATP, 0.2 Na2GTP and 0.1 leupeptin (pH 7.2–7.3, 265–270 mOsm). Electrode resistance was typically 4–5 MΩ in the bath. After seal rupture, series resistance was compensated (70–90%) and periodically monitored. Only data from cells for which access resistance values were smaller than 20 MΩ were included. Membrane capacitances and input resistances were measured to compare membrane properties between neurons from WT and transgenic mice. Drugs were applied through an array of application capillaries positioned 500–600 μm from the cell using a pressure-driven fast perfusion system. NMDA was applied for 3 sec every 10 sec. Responsiveness of cells to 100 μM NMDA and their sensitivity to 50 μM Mg2+ were examined at two different holding potentials: -70 and -40 mV. The NMDA receptor specific antagonist 2-amino-5-phosphonovalerate was applied to confirm the specificity of NMDA-induced currents (data not shown). To normalize to cell size, peak current densities were measured by dividing peak amplitude values by the capacitance of the cell.
Values in the figures and text are presented as mean ± standard error (SE). Appropriate student's t-tests alone were used when two group means were compared. Electrophysiological membrane properties and NMDA current characteristics were compared using appropriate two-way analyses of variance (ANOVAs) with one repeated measure followed by multiple comparisons using Bonferroni t-tests. Differences between means were considered statistically significant if P < 0.05.
We would like to thank Kenneth Campbell (Children's Hospital Research Foundation, Cincinnati) for providing the Dlx5/6-Cre mice. This work was generously supported by grants from the Hereditary Disease Foundation (HDF) and NS049501 to X.W. Yang, and NS41574 to M.S. Levine. We would like to thank N. S. Wexler and C. Johnson for their tremendous support of this project; and members of the Yang laboratory for discussions and comments on the manuscript.
- Sharp AH, Ross CA: Neurobiology of Huntington's disease. Neurobiol Dis. 1996, 3 (1): 3-15. 10.1006/nbdi.1996.0002.View ArticlePubMedGoogle Scholar
- A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993, 72 (6): 971-983. 10.1016/0092-8674(93)90585-E.Google Scholar
- Zoghbi HY, Orr HT: Glutamine repeats and neurodegeneration. Annu Rev Neurosci. 2000, 23: 217-247. 10.1146/annurev.neuro.23.1.217.View ArticlePubMedGoogle Scholar
- Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, Starr E, Squitieri F, Lin B, Kalchman MA, et al: The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet. 1993, 4 (4): 398-403. 10.1038/ng0893-398.View ArticlePubMedGoogle Scholar
- Bates G, Lehrach H: Trinucleotide repeat expansions and human genetic disease. Bioessays. 1994, 16 (4): 277-284. 10.1002/bies.950160411.View ArticlePubMedGoogle Scholar
- Craufurd D, Dodge A: Mutation size and age at onset in Huntington's disease. J Med Genet. 1993, 30 (12): 1008-1011.PubMed CentralView ArticlePubMedGoogle Scholar
- MacMillan JC, Snell RG, Tyler A, Houlihan GD, Fenton I, Cheadle JP, Lazarou LP, Shaw DJ, Harper PS: Molecular analysis and clinical correlations of the Huntington's disease mutation. Lancet. 1993, 342 (8877): 954-958. 10.1016/0140-6736(93)92002-B.View ArticlePubMedGoogle Scholar
- Rubinsztein DC, Barton DE, Davison BC, Ferguson-Smith MA: Analysis of the huntingtin gene reveals a trinucleotide-length polymorphism in the region of the gene that contains two CCG-rich stretches and a correlation between decreased age of onset of Huntington's disease and CAG repeat number. Hum Mol Genet. 1993, 2 (10): 1713-1715. 10.1093/hmg/2.10.1713.View ArticlePubMedGoogle Scholar
- Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, Rye D, Ferrante RJ, Hersch SM, Li XJ: Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci. 1999, 19 (7): 2522-2534.PubMedGoogle Scholar
- Vonsattel JP, DiFiglia M: Huntington disease. J Neuropathol Exp Neurol. 1998, 57 (5): 369-384.View ArticlePubMedGoogle Scholar
- Nance MA, Myers RH: Juvenile onset Huntington's disease--clinical and research perspectives. Ment Retard Dev Disabil Res Rev. 2001, 7 (3): 153-157. 10.1002/mrdd.1022.View ArticlePubMedGoogle Scholar
- Schilling G, Sharp AH, Loev SJ, Wagster MV, Li SH, Stine OC, Ross CA: Expression of the Huntington's disease (IT15) protein product in HD patients. Hum Mol Genet. 1995, 4 (8): 1365-1371. 10.1093/hmg/4.8.1365.View ArticlePubMedGoogle Scholar
- Sharp AH, Loev SJ, Schilling G, Li SH, Li XJ, Bao J, Wagster MV, Kotzuk JA, Steiner JP, Lo A, et al: Widespread expression of Huntington's disease gene (IT15) protein product. Neuron. 1995, 14 (5): 1065-1074. 10.1016/0896-6273(95)90345-3.View ArticlePubMedGoogle Scholar
- Mitchell IJ, Cooper AJ, Griffiths MR: The selective vulnerability of striatopallidal neurons. Prog Neurobiol. 1999, 59 (6): 691-719. 10.1016/S0301-0082(99)00019-2.View ArticlePubMedGoogle Scholar
- Tang TS, Tu H, Chan EY, Maximov A, Wang Z, Wellington CL, Hayden MR, Bezprozvanny I: Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron. 2003, 39 (2): 227-239. 10.1016/S0896-6273(03)00366-0.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhai W, Jeong H, Cui L, Krainc D, Tjian R: In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell. 2005, 123 (7): 1241-1253. 10.1016/j.cell.2005.10.030.View ArticlePubMedGoogle Scholar
- Zucker B, Luthi-Carter R, Kama JA, Dunah AW, Stern EA, Fox JH, Standaert DG, Young AB, Augood SJ: Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1. Hum Mol Genet. 2005, 14 (2): 179-189. 10.1093/hmg/ddi014.View ArticlePubMedGoogle Scholar
- DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N: Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997, 277 (5334): 1990-1993. 10.1126/science.277.5334.1990.View ArticlePubMedGoogle Scholar
- Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li XJ, Stevens ME, Rosemond E, Roder JC, Phillips AG, Rubin EM, Hersch SM, Hayden MR: A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 1999, 23 (1): 181-192. 10.1016/S0896-6273(00)80764-3.View ArticlePubMedGoogle Scholar
- Wellington CL, Ellerby LM, Gutekunst CA, Rogers D, Warby S, Graham RK, Loubser O, van Raamsdonk J, Singaraja R, Yang YZ, Gafni J, Bredesen D, Hersch SM, Leavitt BR, Roy S, Nicholson DW, Hayden MR: Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J Neurosci. 2002, 22 (18): 7862-7872.PubMedGoogle Scholar
- Zhou H, Cao F, Wang Z, Yu ZX, Nguyen HP, Evans J, Li SH, Li XJ: Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity. J Cell Biol. 2003, 163 (1): 109-118. 10.1083/jcb.200306038.PubMed CentralView ArticlePubMedGoogle Scholar
- Li S, Li XJ: Multiple pathways contribute to the pathogenesis of Huntington disease. Mol Neurodegener. 2006, 1: 19-10.1186/1750-1326-1-19.PubMed CentralView ArticlePubMedGoogle Scholar
- Cepeda C, Hurst RS, Flores-Hernandez J, Hernandez-Echeagaray E, Klapstein GJ, Boylan MK, Calvert CR, Jocoy EL, Nguyen OK, Andre VM, Vinters HV, Ariano MA, Levine MS, Mathern GW: Morphological and electrophysiological characterization of abnormal cell types in pediatric cortical dysplasia. J Neurosci Res. 2003, 72 (4): 472-486. 10.1002/jnr.10604.View ArticlePubMedGoogle Scholar
- Shin JY, Fang ZH, Yu ZX, Wang CE, Li SH, Li XJ: Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol. 2005, 171 (6): 1001-1012. 10.1083/jcb.200508072.PubMed CentralView ArticlePubMedGoogle Scholar
- Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, Timmusk T, Sipione S, Cattaneo E: Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science. 2001, 293 (5529): 493-498. 10.1126/science.1059581.View ArticlePubMedGoogle Scholar
- Baquet ZC, Gorski JA, Jones KR: Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci. 2004, 24 (17): 4250-4258. 10.1523/JNEUROSCI.3920-03.2004.View ArticlePubMedGoogle Scholar
- Gu X, Li C, Wei W, Lo V, Gong S, Li SH, Iwasato T, Itohara S, Li XJ, Mody I, Heintz N, Yang XW: Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron. 2005, 46 (3): 433-444. 10.1016/j.neuron.2005.03.025.View ArticlePubMedGoogle Scholar
- Butt SJ, Fuccillo M, Nery S, Noctor S, Kriegstein A, Corbin JG, Fishell G: The temporal and spatial origins of cortical interneurons predict their physiological subtype. Neuron. 2005, 48 (4): 591-604. 10.1016/j.neuron.2005.09.034.View ArticlePubMedGoogle Scholar
- Stenman J, Toresson H, Campbell K: Identification of two distinct progenitor populations in the lateral ganglionic eminence: implications for striatal and olfactory bulb neurogenesis. J Neurosci. 2003, 23 (1): 167-174.PubMedGoogle Scholar
- Svenningsson P, Nishi A, Fisone G, Girault JA, Nairn AC, Greengard P: DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol. 2004, 44: 269-296. 10.1146/annurev.pharmtox.44.101802.121415.View ArticlePubMedGoogle Scholar
- Starling AJ, Andre VM, Cepeda C, de Lima M, Chandler SH, Levine MS: Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease. J Neurosci Res. 2005, 82 (3): 377-386. 10.1002/jnr.20651.View ArticlePubMedGoogle Scholar
- Joshi PR, Gomez Y, Levine MS: 2006, On SfN website, Abstracts/Symposia-Altered striatal AMPA receptor function in the R6/2 mouse model of Huntington’s disease: 14-18 Oct 2006; Atlanta. Huntington's Disease: ModelsGoogle Scholar
- Andre VM, Cepeda C, Venegas A, Gomez Y, Levine MS: Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease. J Neurophysiol. 2006, 95 (4): 2108-2119. 10.1152/jn.01118.2005.View ArticlePubMedGoogle Scholar
- Ali NJ, Levine MS: Changes in expression of N-methyl-D-aspartate receptor subunits occur early in the R6/2 mouse model of Huntington's disease. Dev Neurosci. 2006, 28 (3): 230-238. 10.1159/000091921.View ArticlePubMedGoogle Scholar
- Cepeda C, Ariano MA, Calvert CR, Flores-Hernandez J, Chandler SH, Leavitt BR, Hayden MR, Levine MS: NMDA receptor function in mouse models of Huntington disease. J Neurosci Res. 2001, 66 (4): 525-539. 10.1002/jnr.1244.View ArticlePubMedGoogle Scholar
- Luthi-Carter R, Apostol BL, Dunah AW, DeJohn MM, Farrell LA, Bates GP, Young AB, Standaert DG, Thompson LM, Cha JH: Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation. Neurobiol Dis. 2003, 14 (3): 624-636. 10.1016/j.nbd.2003.08.024.View ArticlePubMedGoogle Scholar
- Cepeda C, Hurst RS, Calvert CR, Hernandez-Echeagaray E, Nguyen OK, Jocoy E, Christian LJ, Ariano MA, Levine MS: Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci. 2003, 23 (3): 961-969.PubMedGoogle Scholar
- Bezprozvanny I, Hayden MR: Deranged neuronal calcium signaling and Huntington disease. Biochem Biophys Res Commun. 2004, 322 (4): 1310-1317. 10.1016/j.bbrc.2004.08.035.View ArticlePubMedGoogle Scholar
- Li L, Fan M, Icton CD, Chen N, Leavitt BR, Hayden MR, Murphy TH, Raymond LA: Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. Neurobiol Aging. 2003, 24 (8): 1113-1121. 10.1016/j.neurobiolaging.2003.04.003.View ArticlePubMedGoogle Scholar
- Shehadeh J, Fernandes HB, Zeron Mullins MM, Graham RK, Leavitt BR, Hayden MR, Raymond LA: Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiol Dis. 2006, 21 (2): 392-403. 10.1016/j.nbd.2005.08.001.View ArticlePubMedGoogle Scholar
- Hansson O, Castilho RF, Korhonen L, Lindholm D, Bates GP, Brundin P: Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. J Neurochem. 2001, 78 (4): 694-703. 10.1046/j.1471-4159.2001.00482.x.View ArticlePubMedGoogle Scholar
- Li L, Murphy TH, Hayden MR, Raymond LA: Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. J Neurophysiol. 2004, 92 (5): 2738-2746. 10.1152/jn.00308.2004.View ArticlePubMedGoogle Scholar
- Nicniocaill B, Haraldsson B, Hansson O, O'Connor WT, Brundin P: Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice. Eur J Neurosci. 2001, 13 (1): 206-210. 10.1046/j.0953-816X.2000.01379.x.View ArticlePubMedGoogle Scholar
- Boston-Howes W, Gibb SL, Williams EO, Pasinelli P, Brown RH, Trotti D: Caspase-3 cleaves and inactivates the glutamate transporter EAAT2. J Biol Chem. 2006, 281 (20): 14076-14084. 10.1074/jbc.M600653200.View ArticlePubMedGoogle Scholar
- Ganel R, Ho T, Maragakis NJ, Jackson M, Steiner JP, Rothstein JD: Selective up-regulation of the glial Na+-dependent glutamate transporter GLT1 by a neuroimmunophilin ligand results in neuroprotection. Neurobiol Dis. 2006, 21 (3): 556-567. 10.1016/j.nbd.2005.08.014.View ArticlePubMedGoogle Scholar
- Rothstein JD, Martin LJ, Kuncl RW: Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med. 1992, 326 (22): 1464-1468.View ArticlePubMedGoogle Scholar
- Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, Cataudella T, Leavitt BR, Hayden MR, Timmusk T, Rigamonti D, Cattaneo E: Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet. 2003, 35 (1): 76-83. 10.1038/ng1219.View ArticlePubMedGoogle Scholar
- Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, Cleveland DW: Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006, 312 (5778): 1389-1392. 10.1126/science.1123511.View ArticlePubMedGoogle Scholar
- Higuchi M, Zhang B, Forman MS, Yoshiyama Y, Trojanowski JQ, Lee VM: Axonal degeneration induced by targeted expression of mutant human tau in oligodendrocytes of transgenic mice that model glial tauopathies. J Neurosci. 2005, 25 (41): 9434-9443. 10.1523/JNEUROSCI.2691-05.2005.View ArticlePubMedGoogle Scholar
- Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM: Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 2002, 34 (4): 521-533. 10.1016/S0896-6273(02)00682-7.View ArticlePubMedGoogle Scholar
- Custer SK, Garden GA, Gill N, Rueb U, Libby RT, Schultz C, Guyenet SJ, Deller T, Westrum LE, Sopher BL, La Spada AR: Bergmann glia expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by impairing glutamate transport. Nat Neurosci. 2006, 9 (10): 1302-1311. 10.1038/nn1750.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.